These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 4012342)

  • 1. Drug sensitivity test for patients with acute leukemia on high-dose ara-C therapy.
    Momparler RL; Onetto N; Momparler LF; Gyger M; Leclerc JM; Rivard GE
    Semin Oncol; 1985 Jun; 12(2 Suppl 3):31-3. PubMed ID: 4012342
    [No Abstract]   [Full Text] [Related]  

  • 2. Sequential high-dose ara-C and asparaginase in the therapy of previously treated and untreated patients with acute leukemia.
    Capizzi RL; Powell BL; Cooper MR; Stuart JJ; Muss HB; Richards F; Jackson DV; White DR; Spurr CL; Zekan PJ
    Semin Oncol; 1985 Jun; 12(2 Suppl 3):105-13. PubMed ID: 3892697
    [No Abstract]   [Full Text] [Related]  

  • 3. Pharmacologically directed ara-C therapy for refractory leukemia.
    Plunkett W; Iacoboni S; Estey E; Danhauser L; Liliemark JO; Keating MJ
    Semin Oncol; 1985 Jun; 12(2 Suppl 3):20-30. PubMed ID: 4012338
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro and in vivo assessment of sensitivity to ara-C in myeloid leukemias.
    Raza A; Ucar K; Preisler HD; Mayers G
    Semin Oncol; 1985 Jun; 12(2 Suppl 3):9-19. PubMed ID: 3892706
    [No Abstract]   [Full Text] [Related]  

  • 5. [Principles of high-dose cytarabinoside treatment].
    Seeber S
    Onkologie; 1985 Feb; 8(1):4-7. PubMed ID: 3885120
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dose-related pharmacologic effects of high-dose ara-C and its self-potentiation.
    Capizzi RL; Yang JL; Rathmell JP; White JC; Cheng E; Cheng YC; Kute T
    Semin Oncol; 1985 Jun; 12(2 Suppl 3):65-74. PubMed ID: 3892704
    [No Abstract]   [Full Text] [Related]  

  • 7. Treatment of leukemia with low-dose ara-C: a study of 160 cases.
    Degos L; Castaigne S; Tilly H; Sigaux F; Daniel MT
    Semin Oncol; 1985 Jun; 12(2 Suppl 3):196-9. PubMed ID: 4012337
    [No Abstract]   [Full Text] [Related]  

  • 8. [High-dose Ara-C treatment of acute leukemia].
    Takaku F
    Gan To Kagaku Ryoho; 1986 May; 13(5):1823-8. PubMed ID: 3707145
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Relationship between the expression of the genes encoding the key enzymes for cytarabine metabolism and the pharmacokinetics of cytarabine in the treatment of childhood acute leukemia with high-dose cytarabine].
    Xie XT; Jiang SY; Li BS; Yang LL
    Zhonghua Er Ke Za Zhi; 2008 Apr; 46(4):276-80. PubMed ID: 19099730
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of leukemia with low dose Ara-C: a study of 159 cases.
    Castaigne S; Tilly H; Sigaux F; Daniel MT; Degos L
    Haematol Blood Transfus; 1985; 29():56-9. PubMed ID: 3896976
    [No Abstract]   [Full Text] [Related]  

  • 11. Cellular and clinical pharmacology of low-dose ara-C.
    Kufe DW; Griffin JD; Spriggs DR
    Semin Oncol; 1985 Jun; 12(2 Suppl 3):200-7. PubMed ID: 3925558
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [A therapeutic trial with low-dose Ara-C in acute nonlymphocytic leukemia and myelodysplastic syndromes: a study of 15 cases].
    Maruta A; Miyashita H; Kodama F; Harano H; Kanamori H; Takahashi K; Noguchi T; Matsuzaki M; Ogawa K; Motomura S
    Rinsho Ketsueki; 1988 Jan; 29(1):8-13. PubMed ID: 3385938
    [No Abstract]   [Full Text] [Related]  

  • 13. Intensive postremission therapy in adults with acute nonlymphocytic leukemia with ara-C by continuous infusion or bolus administration: preliminary results of a CALGB phase I study.
    Mayer RJ; Schiffer CA; Peterson BA; Silver RT; Cornwell GG; McIntyre OR; Rai KR; Budman DR; Ellison RR; Maguire M
    Semin Oncol; 1985 Jun; 12(2 Suppl 3):84-90. PubMed ID: 4012343
    [No Abstract]   [Full Text] [Related]  

  • 14. [High-dose cytarabine treatment in acute leukemias and leukemic meningiosis: clinical aspects and pharmacokinetics].
    Nowrousian MR; Seeber S; Miller AA; Anders C; Ohl S; Schmidt CG
    Onkologie; 1985 Feb; 8(1):26-32. PubMed ID: 3885117
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Experiences with low-dos Ara-C in the therapy of hematological neoplasms].
    Jacky E; Frick P
    Ther Umsch; 1988 Feb; 45(2):119-23. PubMed ID: 3358244
    [No Abstract]   [Full Text] [Related]  

  • 16. [Intermediate- and high-dose cytosine arabinoside therapy in acute refractory leukemia].
    Ohshima A; Yoshida K; Sato T; Miyazaki S; Yanagisawa M; Nakayama Y; Takahashi T; Mamiya S; Fukusima Y; Miura AB
    Gan To Kagaku Ryoho; 1987 Jan; 14(1):192-5. PubMed ID: 3800405
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Variables predicting response to high dose cytosine arabinoside therapy in patients with refractory acute leukemia.
    Estey E; Plunkett W; Dixon D; Keating M; McCredie K; Freireich EJ
    Leukemia; 1987 Aug; 1(8):580-3. PubMed ID: 3669771
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Results of high-dose cytarabine therapy. A review].
    Gassmann W; Schmitz N; Löffler H
    Onkologie; 1985 Feb; 8(1):8-15. PubMed ID: 3885125
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of amsacrine on ara-CTP cellular pharmacology in human leukemia cells during high-dose cytarabine therapy.
    Plunkett W; Nowak B; Keating MJ
    Cancer Treat Rep; 1987 May; 71(5):479-83. PubMed ID: 3567973
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intracellular pharmacodynamic studies of the synergistic combination of 6-mercaptopurine and cytosine arabinoside in human leukemia cell lines.
    Ramilo-Torno LV; Avramis VI
    Cancer Chemother Pharmacol; 1995; 35(3):191-9. PubMed ID: 7805176
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.